Advanced search
Publication Cover
Expert Review of Vaccines Volume 9, 2010 - Issue 4
Submit an article Journal homepage
67
Views
7
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Safety and immunogenicity of influenza A H1N1 vaccines

Wei Lu Medical Officer, Department of Medicine, National University Hospital, National University of Singapore, 5 Lower Kent Ridge Road, 119074, Singapore
&
Paul A Tambyah Associate Professor of Medicine, Department of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, 119074, Singapore. [email protected]
Pages 365-369 | Published online: 09 Jan 2014

References

  • Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet375, 56–66 (2010).
  • CDC. Swine influenza A (H1N1) infection in two children – southern California, March–April 2009. MMWR Morb. Mortal. Wkly Rep.58, 400–402 (2009).
  • CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly Rep.58, 521–524 (2009).
  • CDC. Effectiveness of 2008–2009 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) – United States, May–June 2009. MMWR Morb. Mortal. Wkly Rep.58, 1241–1245 (2009).
  • Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med.361, 1945–1952 (2009).
  • CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis – North Carolina, 2009. MMWR Morb. Mortal. Wkly Rep.58, 969–972 (2009).
  • Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine20(Suppl. 5), B40–B44 (2002).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354, 1343–1351 (2006).
  • Bresson JL, Perronne C, Launary O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367, 1657–1664 (2006).
  • Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet368, 991–997 (2006).
  • Ehrlich HJ, Müller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358, 2573–2584 (2008).
  • Chen H, Wang Y, Liu W et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg. Infect. Dis.15, 1849–1850 (2009).
  • Plennevaux E, Sheldon E, Blatter M et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled Phase 2 trials. Lancet375, 41–48 (2010).
  • Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–2010 influenza season: a multicentre, randomised controlled trial. Lancet375, 49–55 (2010).
  • Baldo V, Baldovin T, Floreani A et al. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine25, 3955–3961 (2007).
  • Greenberg ME, Lai MH, Hartel GF et al. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N. Engl. J. Med.361, 2405–2413 (2009).
  • Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med.361, 2414–2423 (2009).
  • McConnell J. Influenza in the Asia Pacific. Lancet Infect. Dis.9, 590–591 (2009).
  • Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol.16, 265–273 (2009).
  • Li OT, Poon LL. One step closer to universal influenza epitopes. Expert Rev. Anti Infect Ther.6, 687–690 (2009).
  • Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol.333, 197–210 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.